PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Steg, Philippe Gabriel
TI  - Prehospital Bivalirudin Improved Outcomes versus Heparin in Patients with Myocardial Infarction
DP  - 2013  01
TA  - MD Conference Express
PG  - 18--19
VI  - 13
IP  - 19
4099  - http://mdc.sagepub.com/content/13/19/18.short
4100  - http://mdc.sagepub.com/content/13/19/18.full
AB  - The HORIZONS AMI trial showed that bivalirudin therapy in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous intervention (PCI) reduced mortality and bleeding for up to 3 years compared with heparin plus a glycoprotein IIb/IIIa inhibitor [Stone GW et al. N Engl J Med 2008]. However, according to the results of the European Ambulance Acute Coronary Syndrome Angiography Trial [EUROMAX; Steg PG et al. N Engl J Med 2013], several issues remain. The objective of the EUROMAX trial was to examine whether bivalirudin, initiated in patients with STEMI while being transported in the ambulance for primary PCI, was superior to heparin and provisional use of glycoprotein IIb/IIIa inhibitors.